Core Capital Management & Research inc. Makes New $4.73 Million Investment in Bristol Myers Squibb Company $BMY

Core Capital Management & Research inc. purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 82,074 shares of the biopharmaceutical company’s stock, valued at approximately $4,729,000. Bristol Myers Squibb makes up 2.5% of Core Capital Management & Research inc.’s holdings, making the stock its 13th largest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth $25,000. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb in the second quarter worth $27,000. Bayban acquired a new stake in Bristol Myers Squibb in the fourth quarter worth $31,000. Finally, Addison Advisors LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $64.46 on Thursday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The business’s 50-day moving average price is $63.39 and its 200 day moving average price is $60.03. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The firm has a market cap of $131.68 billion, a P/E ratio of 14.20, a PEG ratio of 0.31 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on BMY. Guggenheim reaffirmed a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a report on Wednesday, August 5th. Cantor Fitzgerald reissued a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Citigroup reaffirmed a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising arlo-cel multiple myeloma results: Bristol Myers reported positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, or arlo-cel, a potential first-in-class GPRC5D-directed CAR-T therapy. The results could strengthen BMY’s position in heavily pretreated multiple myeloma and expand its growth pipeline. Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
• Positive Sentiment: Pipeline diversification opportunity: Analysts characterized the arlo-cel data as a potentially important addition to Bristol Myers’ cell-therapy portfolio. Success could eventually provide another commercial product to offset patent-expiration and competitive pressures affecting parts of the company’s existing portfolio. Will the Recent Pipeline Progress Boost BMY’s Portfolio Expansion?
• Neutral Sentiment: SOTYKTU growth potential: An industry report sees additional opportunities for BMY’s SOTYKTU in earlier-line treatment, injection-averse patients and new immune-mediated indications. The report is commercially supportive but does not represent a new company announcement or regulatory approval. SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
• Negative Sentiment: CAR-T safety concerns are weighing on the sector: Novartis paused eight experimental CAR-T trials after three patient deaths linked to severe immune reactions. Although the issue involves Novartis, it may increase investor scrutiny of cell-therapy safety, development costs and regulatory risks for BMY’s arlo-cel program. Could Bristol-Myers Squibb Outperform Novartis as CAR-T Safety Concerns Shake the Sector?
• Negative Sentiment: Investors initially sold the news: Reports indicate BMY shares moved lower despite the arlo-cel trial success, suggesting investors may be taking profits or focusing on unanswered questions around safety, approval timing and the therapy’s eventual commercial potential. Bristol-Myers Squibb Stock Heads Into the Open After a 3.2 Percent Drop

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.